Dermatology-focused biopharmaceutical company Verrica Pharmaceuticals Inc. (VRCA) grabbed our attention following a series of regulatory and clinical updates that may shape its near-term trajectory.
Company Overview
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com